Etoricoxib
- Generic Name
- Etoricoxib
- Drug Type
- Small Molecule
- Chemical Formula
- C18H15ClN2O2S
- CAS Number
- 202409-33-4
- Unique Ingredient Identifier
- WRX4NFY03R
- Background
Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.
- Indication
For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.
- Associated Conditions
- Ankylosing Spondylitis (AS), Gout, Osteoarthritis (OA), Rheumatoid Arthritis, Moderate Pain
Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 761
- Registration Number
- NCT00264147
A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis,Osteoarthritis
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 23498
- Registration Number
- NCT00250445
Safety and Efficacy of an Investigational Drug Versus Placebo in the Treatment of Cancer Pain (0663-083)
Phase 2
Withdrawn
- Conditions
- Bone Neoplasms
- First Posted Date
- 2004-11-01
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Registration Number
- NCT00095017
A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED)
Phase 3
Completed
- Conditions
- Osteoarthritis
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 500
- Registration Number
- NCT00092781
An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064)
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 129
- Registration Number
- NCT00092729
Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 4086
- Registration Number
- NCT00092742
An Investigational Drug in Patients With Osteoarthritis (0663-073)
Phase 3
Completed
- Conditions
- Osteoarthritis
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 548
- Registration Number
- NCT00092755
Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)
Phase 3
Completed
- Conditions
- Osteoarthritis
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 6000
- Registration Number
- NCT00092703
A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)
Phase 3
Completed
- Conditions
- Osteoarthritis
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 500
- Registration Number
- NCT00092768
Study of MK0663 in Patients With Chronic Low Back Pain (0663-806)(COMPLETED)
Phase 4
Completed
- Conditions
- Chronic Low Back Pain
- First Posted Date
- 2004-08-27
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 401
- Registration Number
- NCT00090181
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath